IDH2 Antibody (YA4048)

IDH2 (isocitrate dehydrogenase 2) encodes a mitochondrial NADP⁺-dependent isocitrate dehydrogenase that catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate while generating NADPH, thereby supporting mitochondrial metabolism and redox homeostasis^[1][2]. Mechanistically, IDH2 participates in intermediary metabolism through the conversion of isocitrate to 2-oxoglutarate, linking cellular energy metabolism with NADPH production required for biosynthetic and antioxidant processes^[2]. In disease settings, recurrent IDH2 mutations confer a neomorphic enzymatic activity that promotes the production of the oncometabolite 2-hydroxyglutarate (2-HG), which is associated with epigenetic dysregulation and impaired cellular differentiation in malignancies, particularly acute myeloid leukemia (AML) ^[3][4][5]. Therefore, mutant IDH2 has become an important molecular target in cancer research and precision oncology^[3][5]. Compared with related isoforms, IDH1 and IDH2 both utilize NADP⁺ and catalyze the same biochemical reaction, whereas IDH2 is localized to mitochondria, distinguishing its metabolic context from the cytosolic IDH1 isoform^[2][5]. For experimental and translational applications, enasidenib is a selective small-molecule inhibitor of mutant IDH2 that reduces 2-HG levels and promotes myeloid differentiation, providing a widely used pharmacological tool for investigating mutant IDH2 biology and therapeutic response mechanisms in AML models^[3][5][6].